Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET

CHENGDU, China, May 7 TianyinPharmaceutical Co., Inc., (NYSE Amex: TPI), a biopharmaceutical company thatdevelops, manufactures and sells modernized traditional Chinese medicine("TCM") and branded generics based in Chengdu, China, today announced that thesenior management will host a conference call to discuss its fiscal 2010 thirdquarter results at 9:00 a.m. ET on Wednesday, May 12, 2010.

Interested parties may access the call by dialing +1-877-941-4776 (U.S.),or +1-480-629-9762 (International). The conference ID is 4297414. It isadvisable to dial in approximately 5-10 minutes prior to the start of the call.

A replay will be available through May 26, 2010 and can be accessed bydialing +1-800-406-7325 (U.S.), or +1-303-590-3030 (International), passcode4297414.

This call is being web cast by ViaVid Broadcasting and can be accessed atViaVid's website at the following link:http://viavid.net/dce.aspx?sid=00007515

This event is optimized for Microsoft's Windows media player version 9. Todownload, please go to http://www.microsoft.com/windows/windowsmedia/download .

About Tianyin Pharmaceutical

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, SichuanProvince of China, is a leading biopharmaceutical company that specializes inthe development, manufacturing, marketing and sale of modernized traditionalChinese medicines and branded generics. Tianyin is equipped with twostate-of-the-art manufacturing facilities and an extensive nationwide salesand distribution network throughout China. Tianyin currently manufactures andmarkets a comprehensive portfolio of 50 products, of which 23 are listed inthe highly selective National Medicine Catalog of the National MedicalInsurance program, 7 are included in the essential drug list of China. Tianyinachieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12products pending regulatory approval that target various indications withconsiderable market potential. Tianyin has an extensive nationwidedistribution network with a sales force of 720 sales representatives out oftotaled 1,365 employees. For more information about Tianyin, please visithttp://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: Tianyin Pharmaceutical Co., Inc. James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Add: 23rd Floor Unionsun Yangkuo Plaza No. 2, Block 3, South Renmin Road Chengdu, 610041 China Web: http://www.tianyinpharma.com Email: [email protected] Tel: +86-28-8551-6696 (Chengdu, China) +1-949-350-6999 (U.S.)

SOURCE Tianyin Pharmaceutical Co., Inc.